RxDoctor Payments Data

Tigran Tiraturyan, MD

Hospitalist · Glendale, CANPI 1134650435

Payments from drug & device makers

$1,204in general payments, 2019–2025

Across 20 payments — averaging $60.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$601
  • Abbott$169
  • Johnson & Johnson$135
  • Esperion Therapeutics, Inc.$125
  • Janssen Scientific Affairs, LLC$125
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$33
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$1,204100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,204 in reported general payments places this provider in the 90th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$456,876
Medicare patients
825
Services billed
3,652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban110$38,169
JanuviaSitagliptin Phosphate30$10,513
SantylCollagenase Clostridium Hist.28$9,492
FarxigaDapagliflozin Propanediol22$6,724
Memantine Hcl ErMemantine Hcl13$2,934
XareltoRivaroxaban11$2,768
Carbidopa-LevodopaCarbidopa/Levodopa26$1,799
Pantoprazole Sodium67$1,796
Atorvastatin Calcium118$1,557
Gabapentin65$1,182
Amlodipine Besylate108$824
Cilostazol17$669
Midodrine Hcl12$660
Tamsulosin Hcl40$653
Finasteride31$525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$135$2,76811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,469 hospitalist providers in California.

Other hospitalist in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →